Use of an active substance that binds to CD28 for producing a pharmaceutical composition for treatment of B-CLL

摘要

Making a pharmaceutical composition, comprising using a superagonistic monoclonal antibody (mAb), is new. This mAb is specific for a natural costimulation receptor, which is expressed on T cells or a mimic compound ACTIVITY : Cytostatic; Immunostimulant; Antianemic. No biological data is given. MECHANISM OF ACTION : None given.